De-Escalating the Management of In Situ and Invasive Breast Cancer

Fernando A. Angarita, Robert Brumer, Matthew Castelo, Nestor F. Esnaola, Stephen B. Edge, Kazuaki Takabe

Research output: Contribution to journalReview articlepeer-review

Abstract

It is necessary to identify appropriate areas of de-escalation in breast cancer treatment to minimize morbidity and maximize patients’ quality of life. Less radical treatment modalities, or even no treatment, have been reconsidered if they offer the same oncologic outcomes as standard therapies. Identifying which patients benefit from de-escalation requires particular care, as standard therapies will continue to offer adequate cancer outcomes. We provide an overview of the literature on the de-escalation of treatment of ductal carcinoma in situ (DCIS), local treatment of breast cancer, and surgery after neoadjuvant systemic therapy. De-escalation of breast cancer treatment is a key area of investigation that will continue to remain a priority. Improvements in understanding the natural history and biology of breast cancer, imaging modalities, and adjuvant treatments will expand this even further. Future efforts will continue to challenge us to consider the true role of various treatment modalities.

Original languageEnglish (US)
Article number4545
JournalCancers
Volume14
Issue number19
DOIs
StatePublished - Oct 2022

Keywords

  • breast cancer
  • breast surgery
  • de-escalation
  • ductal carcinoma in situ
  • neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'De-Escalating the Management of In Situ and Invasive Breast Cancer'. Together they form a unique fingerprint.

Cite this